The average accuracy ranged JNK Signaling Pathway from 5.9% to 9.0%. Pharmacokinetic data on plasma concentrations of neratinibwere analyzed for each subject with a non-compartmental method using WinNonlin version 4.1 business applications. The maximum plasma concentration and T max were determined directly from the concentration data.The observed terminal velocity constant phase was observed by a log-linear regression of the terminal part of the monoexponential curve of the concentration-time-Sch Estimates plasma. The half-life was calculated as 0.693/lz. The liquid surface Cut under the concentration-time curve to the last recorded plasma concentration at time t, was calculated using the trapezoidal rule may need during the ascending part of the curve and the rule logtrapezoidal need during the descending part of the curve. Total AUC AUC AUCt ct / lz shops protected. AUC: Access is calculated as the ratio of the dose ratio. The apparent volume of distribution for the terminal phase was calculated as the ratio Ratio of CL / F for LZ. Statistical methods for a sample of 24 was hlt weight, To quantify drug interaction drug ketoconazole on neratinib. Descriptive Statistics for plasma concentrations at any point during this period and the pharmacokinetic parameters for each of the processing parameters were calculated PK separately.The neratinib derived from neratinib administered alone and with ketoconazole administered with an analysis of variance compared to a crossover twoperiod design.Additionally, The geometric mean values, AUC and Cmax AUC Cmax and 90% confidence intervals were calculated to Ausma it the effect of ketoconazole sch COLUMNS on the pharmacokinetics of neratinib. Results of the study from 27 October 2006 to 12th Chern november 2006.Twenty four F Were performed ENR Strips. Subjects aged 19-48 years were, 23 were M Men, 16 were Caucasian, seven were African American and 1 was Asian. BMI was 18.9 to 30.5 kgm second Twenty-one subject completed study. A subject that the drug due to an AE and two for other reasons set.
Blood samples for pharmacokinetic analysis were available Chern PK 22 F. The average plasma concentrations neratinib h Ago following administration of ketoconazole after neratinib neratinib were alone, as shown in Figure 1. The pharmacokinetic parameters for both systems are summarized in Table 1. Co-administration of ketoconazole increased Hte exposure to neratinib. For Cmax, the average value of 55 ng ml of 1-201 ng ml 1 increased Ht. For CSA, the average number of 903 ng ml 1 h to 4660 ng ML 1 h log transformed ANOVA showed that the treatment effect was significant for Cmax and AUC. The ratio Ratio of geometric mean square neratinib cooperation with ketoconazole was administered alone for Cmax neratinib 3.2 and AUC 4.8. The median tmax was 6.0 h for both regimens. Co-administration of ketoconazole reduced the mean apparent oral clearance of 346 neratinib 1 to 87.1 LH and LH increased Hten the elimination half-life of 11.7 h to 18.0 h. And safety reps Opportunity for the treatment of adverse events occurred in 20 of 24 patients were shown in Table 2.There, no clinically significant differences were found in the H FREQUENCY or severity of side effects of treatment between the two treatments. Gastrointestinal events were the hours Ufigsten side effects were mild to moderate, with the exception.